Physician profile
David B Drury
NPI 1124093380
$7,988.51
in general payments reported to CMS, 2019-2025
33 companies · $668 in 2025
The $668 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,789 · 2020: $1,123 · 2021: $1,313 · 2022: $1,118 · 2023: $968 · 2024: $1,009 · 2025: $668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,645.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,645.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,235.48 | 2019-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $1,055.36 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $995.07 | 2019-2025 | Jardiance, Ofev |
| Astrazeneca Pharmaceuticals LP | $816.49 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $643.87 | 2019-2025 | Mounjaro, Zepbound, Trulicity |
| Bayer Healthcare Pharmaceuticals INC. | $387.96 | 2022-2025 | |
| Amgen INC. | $377.08 | 2019-2025 | Otezla, Repatha, Evenity |
| Dexcom, INC. | $316.79 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $315.01 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $301.15 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Abbvie INC. | $286.77 | 2021-2023 | Vraylar |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $258.19 | 2019-2024 | Xifaxan |
| Pfizer INC. | $257.15 | 2019-2024 | |
| Allergan, INC. | $129.41 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $109.12 | 2019-2023 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $80.91 | 2021-2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $56.43 | 2019 | |
| Sunovion Pharmaceuticals INC. | $52.70 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $36.07 | 2021 | |
| Organogenesis INC. | $32.92 | 2025 | Affinity |
| Astellas Pharma US INC | $32.78 | 2021-2024 | Veozah |
| Amarin Pharma, INC. | $29.92 | 2019 | |
| Ferring Pharmaceuticals INC. | $21.40 | 2024 | Euflexxa |
| Exact Sciences Corporation | $20.74 | 2024 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $18.57 | 2022 | |
| Almatica Pharma LLC | $18.45 | 2021 | |
| Corium, LLC | $17.69 | 2023 | Adlarity |
| Kvk-Tech, INC. | $17.67 | 2019 | |
| Ironwood Pharmaceuticals, INC | $16.30 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.03 | 2023 | Quviviq |
| Avion Pharmaceuticals | $14.87 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $14.31 | 2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $6.85 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Drury listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.